It's that time of year again... Annual patent planning for your company/client(s) for next year. Here are some key dates to track as you set your annual patent budget and help your team schedule their priorities: Regular application 12-month filing due dates for your priority applications (e.g. provisionals) filed this year. ⇨ Not only PCTs and regular U.S. app filing due dates, but consider non-PCT countries too. ⇨ For China, consider whether to directly file a utility and u

The $AMRN/Vascepa story... A sad 🥲 but insightful🤔 story about the value of U.S. biopharma patents From ~$23/share to ~$1/share in ~5 yrs Vascepa - the "good" fatty acid in fish oil • Approved for 2 indications ⇨ Pts with very high blood trigs ⇨ Cardiovascular risk reduction • Existing U.S. patents cover Indication 2 and mfg method 📅 Fall 2018 • Vascepa Reduce-It Ph3 cardiovascular risk results • Landmark cardiovascular risk Study ⇨ https://lnkd.in/g4AJ4fhK $$$$AMRN ~$23/s

If you are interested in learning more about prior patent term extension filings, the USPTO and FDA provide some helpful links, which are provided in this post. Two ways that the term of a patent can be extended* are PTA and PTE: 1) Patent Term Adjustment (PTA) is based on delays during patent examination by the USPTO, and 2) Patent Term Extension (PTE) is based on the time it takes a drug from getting the OK from the FDA to start clinical trials to the date of approval as l

March 26, 2023 The U.S. Supreme Court will hear oral arguments tomorrow in Amgen v. Sanofi, an important biotech enablement case. The...